Selective retinoic acid receptor ligands for rheumatoid arthritis

Current Opinion in Investigational Drugs

Volumn 5, Issue 11, 2004, Pages 1153-1157

  Beehler, Blake C ^a   Brinckerhoff, Constance E ^b   Ostrowski, Jacek ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Collagenase; Matrix metalloproteases; Retinoic acid receptor; Retinoid; Rheumatoid arthritis

Indexed keywords

3,7 DIMETHYL 9 (2 NONYLOXYPHENYL) 2,4,6,8 NONATETRAENOIC ACID; 3,7 DIMETHYL 9 [2 NONYLOXY 6 (TRIFLUOROMETHYL)PHENYL] 2,4,6,8 NONATETRAENOIC ACID; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; BMS 189453; BMS 189961; COLLAGENASE; ETRETINATE; FENRETINIDE; INTERLEUKIN 1; ISOTRETINOIN; MATRIX METALLOPROTEINASE; PLACEBO; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID; RETINOL DERIVATIVE; TAC 101; TAMIBAROTENE; UNCLASSIFIED DRUG;

ACNE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME REPRESSION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OUTCOMES RESEARCH; PROMYELOCYTIC LEUKEMIA; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; VISUAL DISORDER;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; MATRIX METALLOPROTEINASES; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 9144246317     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wolfe AM: The epidemiology of rheumatoid arthritis: A review. I. Surveys. Bull Rheum Dis (1968) 19(2 ):518-523.
2. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L: Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis (1998) 57(6 ):350-356.
3. Fuchs HA, Pincus T: Radiographic damage in rheumatoid arthritis: Description by nonlinear models. J Rheumatol (1992) 19(11):1655-1658.
4. Pincus T, Callahan LF: The "side effects" of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol (1993) 32(Suppl 1):28-37.
5. Hamilton K, Clair EW: Tumour necrosis factor-α blockade: A new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother(2000) 1(5):1041-1052.
6. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 46(12):3151-3158.
7. Gomez-Reino JJ, Carmona L, Valverde VR, Mole EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum (2003) 48(8):2122-2127.
8. Bershad SV: The modern age of acne therapy: A review of current treatment options. Mt Sinai J Med (2001) 68 4-5):279-286.
9. Kuenzli S, Saurat JH: Retinoids for the treatment of psoriasis: Outlook for the future. Curr Opin Investig Drugs (2001) 2(5):625-630.
10. Warrell RP: Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med(1996) 47:555-565.
11. Papadimitrakopoulou VA, Hong WK: Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med (1997) 216 2):283-290.
12. Brinckerhoff CE, McMillan RM, Dayer JM, Harris ED: Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N Engl J Med (1980) 303(8):432-436.
13. Lefebvre P: Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord (2001) 1 2):153-164.
14. Wei L: Retinoid receptors and their coregulators. Annu Rev Pharmacol Toxicol (2003) 43:47-72.
15. Pfahl M: Nuclear receptor/AP-1 interaction. Endocr Rev (1993) 14(5):651-658.
16. Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol (2002) 3(3):207-214.
17. Mengshol JA, Mix KS, Brinckerhoff CE: Matrix metalloproteinases as therapeutic targets in arthritic diseases: Bull's-eye or missing the mark? Arthritis Rheum (2002) 46 1):13-20.
18. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW: Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum (1992) 35(1):3542.
19. Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA: Osteoarthritic lesions: Involvement of three different collagenases. Arthritis Rheum (1997) 40(11):2065-2074.
20. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): Mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr (1996) 6 4):391-411.
21. Trentham DE, Brinckerhoff CE: Augmentation of collagen arthritis by synthetic analogues of retinoic acid. J Immunol (1982) 129(6):2668-2672.
22. Brinckerhoff CE, Coffey JW, Sullivan AC: Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13- cis-retinoic acid. Science (1983) 221(4612 ):756-758.
23. Haraoui B, Wilder RL, Allen JB, Sporn MB, Helfgott RK, Brinckerhoff CE: Dose-dependent suppression by the synthetic retinoid, 4-hydroxyphenyl retinamide, of streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol (1985) 7(6):903-916.
24. Wilder RL: Streptococcal cell wall-induced polyarthritis in rats. In: Handbook of Animal Models for the Rheumatic Diseases Greenwald RA, Diamond HS (Eds), CRC Press, Boca Raton, FL, USA (1988):33-40.
25. Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collagen-induced arthritis, an animal model of autoimmunity. Life Sci (1997) 61(19):1861-1878.
26. Hanglow AC, Rosenberger M, Lovey AJ, Nemzek R, Welton AF, Coffey JW: Anti-inflammatory and immuno-modulatory effects of novel retinoid-like 2,4,6,8-nonatetraenoic acids (NTA) in adjuvant-induced arthritis. Agents Actions (1989) 27(3-4):347-350.
27. Fiedler-Nagy C, Wittreich BH, Carey MA: In vitro inhibition of arachidonic acid metabolism by two novel retinoid analogs. Agents Actions (1989) 27(3-4):313-315.
28. Petkovich M, Brand NJ, Krust A, Chambon P: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature (1987) 330(6147):444-450.
29. Kuwabara K, Shudo K, Hori Y: Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett(1996) 378 2):153-156.
30. Nagai H, Matsuura S, Bouda K, Takaoka Y, Wang T, Niwa S, Shudo K: Effect of AM-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology (1999) 58 2):101-112.
31. Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H: Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacology (2003) 67(1):21-31.
32. Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D: Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγ. Proc Natl Acad Sci USA (2000) 97(12):6322-6327.
33. Chen S, Ostrowski J, Whiting G, Roalsvig T, Hammer L, Currier SJ, Honeyman J, Kwasniewski B, Yu KL, Sterzycki R, Kim CU et al: Retinoic acid receptor γ mediates topical retinoid efficacy and irritation in animal models. J Invest Dermatol (1995) 104 5):779-783.
34. Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, Tortolani D, Tramposch KM, Reczek PR: Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol (2003) 30(2):355-363.
35. Geiger JM, Saurat JH: Acitretin and etretinate: How and when they should be used. Dermatol Clin (1993) 11 1):117-129.
36. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, Miller A, Wright V: A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis (1985) 44(3):189-193.
37. Bird HA, Hill J, Sitton NG, Dixon JS, Wright V: A clinical and biochemical evaluation of etretinate in rheumatoid arthritis. Rheumatol Int (1988) 8(2):55-59.
38. Gravallese EM, Handel ML, Coblyn J, Anderson RJ, Sperling RI, Karlson EW, Maier A, Ruderman EM, Formelli F, Weriblatt ME: N [4-hydroxyphenyl] retinamide in rheumatoid arthritis: A pilot study. Arthritis Rheum (1996) 39(6):1021-1026.
39. Plan A (Firm): Innovations in Arthritis Drugs II: 1994-2000. Stanford, CA, USA (1994):223-224.
40. Price JS, Wang-Weigand S, Bohne R, Kozaci LD, Hollander AP: Retinoic acid-induced type II collagen degradation does not correlate with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum (1999) 42(1):137-147.